Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Laurus Labs Ltd

LAURUSLABS:NSI

Laurus Labs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)499.80
  • Today's Change15.80 / 3.26%
  • Shares traded534.81k
  • 1 Year change+38.07%
  • Beta1.4564
Data delayed at least 15 minutes, as of Nov 01 2024 13:51 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. It operates through four divisions: Generics API, Generics FDF, Laurus Synthesis, and Laurus Bio. The Generics API is a third-party API supplier for antiretrovirals. The Generic FDF business focuses on oral solid formulations. The Laurus Synthesis provides drug development and manufacturing services to global pharma, crop science, animal health, and others. The Laurus Bio offers comprehensive services from clone and strain engineering to production, supporting clients across the microbial precision fermentation spectrum. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports.

  • Revenue in INR (TTM)50.53bn
  • Net income in INR1.31bn
  • Incorporated2005
  • Employees6.01k
  • Location
    Laurus Labs LtdSerene Chambers, Road No 7, BanjarahillsHYDERABAD 500034IndiaIND
  • Phone+91 4 039804333
  • Fax+91 4 066594320
  • Websitehttp://www.lauruslabs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sanofi India Ltd23.83bn4.30bn156.48bn2.17k36.4122.8633.446.57186.62229.861,034.61297.261.672.7315.6010,960,440.0030.0822.4257.5530.2155.9555.5218.0421.030.8140435.860.0313135.492.920.573-2.859.64-10.3414.73
Eris Lifesciences Ltd24.98bn3.48bn180.09bn3.08k51.746.4928.917.2125.5725.57183.35203.740.45852.905.968,110,753.006.7313.428.3916.8077.0379.9814.6924.960.85993.410.4626--19.2315.392.576.1527.72--
Wockhardt Ltd28.93bn-3.43bn185.39bn2.39k------6.41-23.75-23.75199.60--------12,084,380.00---4.56---8.2958.6655.26-12.17-12.70--0.0764----5.55-4.7317.17---4.71--
Neuland Laboratories Ltd.16.35bn3.36bn187.40bn1.65k55.76--47.0311.46261.94261.941,274.50--------9,922,259.00--9.25--12.7153.3247.8120.5511.99--29.52--7.1330.8418.5183.5178.7617.8863.45
Astrazeneca Pharma India Ltd13.88bn958.59m190.62bn940.00198.86--171.8713.7438.3438.34555.18--------14,761,520.00--11.78--19.6248.5154.646.9110.27--121.25--25.6229.1712.2162.6624.29-10.46--
Concord Biotech Ltd10.38bn3.13bn191.48bn1.38k61.15--52.1818.4529.9329.9399.19--------7,537,496.00--------77.16--30.18----115.93----19.20--28.33------
Jubilant Pharmova Ltd69.20bn5.93bn191.94bn995.0032.413.2319.862.7737.3837.38436.41375.040.59341.758.1569,544,720.005.052.966.013.5568.5068.478.515.131.202.510.34224.736.70-5.95226.43-33.086.482.13
Alembic Pharmaceuticals Ltd63.04bn6.30bn221.89bn14.86k35.23--24.513.5232.0432.04320.63--------4,242,974.00--10.72--14.2573.1065.989.9912.47--12.52--28.2910.199.6280.071.05-15.5914.87
Pfizer Ltd22.38bn6.18bn233.22bn1.72k37.756.2234.3610.42135.06135.06489.19819.900.52881.8311.1613,004,360.0014.6014.2217.0517.7165.0061.3727.6124.054.3046.210.026782.67-9.551.05-11.645.1433.359.24
Natco Pharma Ltd.42.21bn16.37bn251.28bn4.02k15.35--13.785.9591.3791.37235.68--------10,510,210.00--12.33--14.2583.4073.0538.7725.16--91.13--18.9647.7213.8194.0916.59-4.7114.87
Laurus Labs Ltd50.53bn1.31bn264.86bn6.01k201.926.4048.585.242.432.4393.7076.700.6021.183.068,412,186.001.5510.132.5216.4753.4447.632.5812.830.58181.810.402313.00-16.5517.07-79.6811.3621.6821.67
Gland Pharma Ltd58.58bn7.22bn272.02bn4.22k37.67--24.884.6443.8343.83355.57--------13,890,770.00--13.23--14.5661.0055.5812.3322.92--34.66--7.2656.2922.61-1.1011.3224.02--
Emcure Pharmaceuticals Ltd-100.00bn-100.00bn272.13bn11.15k--------------------------7.14--13.93--59.29--7.81------0.0011.237.14-6.3621.35-5.93--
J B Chemicals and Pharmaceuticals Ltd35.92bn5.87bn304.58bn5.31k53.02--41.458.4836.9936.99226.16--------6,764,044.00--15.77--18.8966.2761.1816.3416.06--21.04--33.0810.6316.2234.8423.3640.1537.42
Suven Pharmaceuticals Ltd9.34bn2.40bn334.35bn1.05k138.89--112.9935.789.469.4636.75--------8,883,019.00--23.17--26.2056.5958.8525.7333.21--33.74--18.63-21.5622.71-26.9922.41-1.83--
Piramal Pharma Ltd87.04bn453.30m354.33bn6.72k787.954.4844.044.070.34070.340766.3659.910.57991.404.8812,954,040.000.302--0.428--63.69--0.5208--0.56037.490.3771--15.39--109.56------
Data as of Nov 01 2024. Currency figures normalised to Laurus Labs Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

24.65%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 03 Oct 202459.17m10.98%
Mirae Asset Investment Managers (India) Pvt Ltd.as of 06 Aug 202415.88m2.95%
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 202414.56m2.70%
The Vanguard Group, Inc.as of 02 Oct 202414.20m2.63%
Barclays Wealth Trustees (India) Pvt Ltd.as of 30 Jun 20246.50m1.21%
Dimensional Fund Advisors LPas of 03 Oct 20245.64m1.05%
Sundaram Asset Management Co. Ltd.as of 30 Sep 20245.02m0.93%
BlackRock Fund Advisorsas of 03 Oct 20244.84m0.90%
Norges Bank Investment Managementas of 30 Jun 20243.61m0.67%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 20243.48m0.65%
More ▼
Data from 30 Jun 2024 - 24 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.